Newly launched ‘Discovery for Clinics’ attracts customers worldwide

Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc., develop software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. It has developed RetinAI Discovery^,  a software platform to enable the right decisions sooner based on evidence, AI-derived insights, automation & data. Discovery is a modular and certified (FDA - 510(K) / CE - MDR) medical image & data platform to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare.

 The latest product addition to the product portfolio is ‘Discovery for Clinics. Along with its expert-level AI models, the platform was designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions and patient management, generating data efficiencies and enhancing clinic decisions. The vendor-neutral and multi-modality platform harmonizes, aggregates, and connects large datasets on a single, cloud-based repository for data. The data is then automatically analyzed with RetinAI’s AI algorithms for accelerated and AI-biomarker based treatment decisions. The AI models can be processed on DICOM and other formats for OCT and fundus imaging.

Both the Ophthalmology and Optometry versions of Discovery for Clinics have progression analytics to help track trends in outcomes and provide powerful visualization to patients on the progression of their disease. The platform connects healthcare stakeholders and patients with Discovery Passport, a feature that allows physicians to securely share their data and remote questionnaires with patients, improve patient engagement, and ultimately continue the quality of care for patients both in and outside the clinic. In both versions, the platform supports referral networks and participation in clinical trials via the collection of Real-World Data (RWD), enabling clinics to generate additional service opportunities. The Ophthalmology version features RUO AI models for a more detailed analysis of Geographic Atrophy, and the ability to look at future atrophy progression through the prediction progression model. 

Global deployment in clinics
Discovery for Clinics is sold directly in Europe and through distributors in countries including the UK, France, Germany, Spain, Italy, Switzerland, Poland, Portugal, Turkey and the Nordic countries. In the US, the startup works through strategic clinical networks such as Retina Consultants of America.

The continued customer support since its establishment in 2017 and product launch has boosted Ikerian's growth. Over the past year, the company has experienced significant growth across all fronts, doubling the number of customers and reaching more than 200% in revenues over the last two years.

(Press release/RAN)